Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carilizumab and Apatinib for Unresectable dMMR Gastric Cancer
NCT06792162Phase 2Recruiting
- Sponsor
- Peking University Third Hospital
- Start
- Apr 2023
- Primary completion
- Apr 2026
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab, Rivoceranib in gastric cancer (GC), sponsored by Peking University Third Hospital. Started Apr 2023; status: recruiting.
02
Drugs
camrelizumabRivoceranib
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT06792162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06792162.